Thanks to intelligent dosing, OnDosis 01 allows for individualization. Every user simply gets the right dose at the right time. And that dose can be set or adjusted to fit a changing need. The device can also be protected, so only the patient can access its contents.
It couldn’t be easier to use OnDosis 01. One push at the button releases the right dose as tiny particles. This makes life easier for patients. Not only do they get the right dose, but it’s also easy to consume.
The smart device connects and integrates with apps to support adherence and self-monitoring. Also, the connectivity to sensors and diagnostics, digital therapeutics and data creates possibilities for improved treatment outcomes.
Today, oral solid medicines is delivered as pills or capsules in bottles or blisters. This makes dose titration and individualization difficult. Tablets or pills may come as 5 mg or 10 mg, but what if the actual need is 7.5 mg? And what if the need changes over time or dosing needs adoption when medicines are initiated?
Besides, standard bottles or blisters don’t monitor compliance or remind patients when they miss a dose.
OnDosis will fix all these issues. With OnDosis, patients get their medicine from an intuitive and handheld device. The dose is just what they need and the drug simple to swallow—which makes it easier to reach the desired outcomes.
OnDosis will benefit millions of people worldwide and our specialty is conditions that require fine-tuned and individualized doses. The result? A much better everyday life and improved health care outcomes.
According to several studies, ADHD patients have problems taking their medicine at the right time (compliance) and to continue their treatment (adherence). There is a high risk of non-medical use, with as many as 1 in 5 of college students has utilized ADHD stimulants for non-medical use. To maintain efficacy and manage side effects, it’s crucial to monitor symptoms and potential side-effects and adjust doses delicately. OnDosis will support more individualization and dose titration, decrease risk of non-medical use, and support compliance and adherence.
Dose titration is vital after organ transplants. Fitting immunosuppression treatments to the individual patient requires frequent dose adjustments. In combination with an expected life-long treatment this makes adherence difficult and over time as many as 30% of these patients become non-adherent. This group also include a large proportion of patients that have problems swallowing. OnDosis resolves dose titration, swallowing difficulties, supports adherence and monitors compliance.
Rare diseases are typically diseases that impact relatively few people and are often serious. The European Commission on Public Health defines rare diseases as "life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them".
Many rare diseases appear early in life. In many cases, dosing of pharmaceuticals used to treat rare diseases are based on body weight or similar metrics. The ability to adjust dosing more precisely to reach the required levels or adjust the dose as the patient grows makes the OnDosis device technology highly suitable for these therapies.